1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Optional) is sponsored by National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC). This program funds small businesses that place a first-time Principal Investigator in charge of a research project, providing support for their mentorship and entrepreneurial training alongside R&D activities.
It encourages participation from individuals underrepresented in the biomedical research workforce, including women-owned small businesses.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: U.S. small businesses with 500 or fewer employees that meet SBA ownership rules for SBIR or STTR. The proposed PI must have never been an independent PI on an NIH or CDC research grant and be a U.S. citizen or lawful permanent resident. Confirm the full requirements in the official notice before applying.
The current listing shows not explicitly stated, but SBIR Phase I and II generally have limits around $306,872 for Phase I and $2,045,816 for Phase II. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Optional) are due January 5, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Optional) is funded by National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
NIH Small Business Transition Grant for New Entrepreneurs (PAR-27-039 SBIR) is sponsored by National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC). This SBIR program funds small businesses led on a project by a first-time Principal Investigator, combining research and development funding with mentorship and entrepreneurial training for that PI. It is returning for fiscal year 2027 and will allow clinical trials. This would be relevant for a small business startup in medical devices for wound healing where the PI is a new entrepreneur.
PHS 2024-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC). This omnibus solicitation supports researcher-initiated ideas in health-related scientific research and development that have strong potential for commercialization and impact on public health, without requiring a clinical trial.
PHS 2023 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC). This omnibus solicitation supports research and development by small businesses of innovative technologies that have the potential to succeed commercially or provide significant societal benefits, including those relevant to mental health.
On November 2, 2026, NIH released NOT-OD-27-006, a draft update to its Policy for Data and Safety Monitoring. As summarized by Harvard's research integrity office, the draft would extend risk-based monitoring from clinical trials to all NIH-supported clinical research, drop the blanket DSMB requirement for Phase 3 and multi-site trials, and require an NIH-approved monitoring plan scaled to risk, effective for applications six months after the final policy. Comments are due January 6, 2027. What it changes and how to respond.
Read articleR&D World's count of NIH RePORTER data shows 13,686 new awards in FY2026, up 21% from 11,272 in FY2025, while total extramural grants fell to about 56,600. New R01s hit 4,960. What the split means for FY2027 applicants.
Read articleTD Charitable Foundation opened its 21st Housing for Everyone round: $10 million in $500,000 grants, about 20 awards, due 4 p.m. November 24, 2026. Last year's round paid 40 grants of $250,000 for eviction prevention. This year's theme is housing stability through renters' income growth: workforce development, credentialing, and financial coaching paired with housing services. Here's what changed, who is eligible from Maine to Florida, and how to build a competitive application in three weeks.
Read article